Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Parent(s) or guardian(s) consent~* 5 to \< 18 years old~* ACH, documented and confirmed by genetic testing~* At least a 6-month period of pretreatment growth assessment in Study 111-901 before study entry~* If sexually active, willing to use a highly effective method of contraception~* Ambulatory and able to stand without assistance~Exclusion criteria:~* Hypochondroplasia or short stature condition other than ACH~* Have any of the following:~  * Hypothyroidism or hyperthyroidism~ * Insulin-requiring diabetes mellitus~ * Autoimmune inflammatory disease~ * Inflammatory bowel disease~ * Autonomic neuropathy~* History of any of the following:~  * Renal insufficiency defined as serum creatinine \> 2 mg/dL~ * Chronic anemia~ * Baseline systolic blood pressure (BP) \< 70 millimeters of mercury (mm Hg) or recurrent symptomatic hypotension (defined as episodes of low BP generally accompanied by symptoms ie, dizziness, fainting) or recurrent symptomatic orthostatic hypotension~ * Cardiac or vascular disease~    * Have a clinically significant finding or arrhythmia on screening electrocardiogram (ECG) that indicates abnormal cardiac function or conduction or Fridericias corrected QTc-F \> 450 msec~* Have an unstable condition likely to require surgical intervention during the study (including progressive cervical medullary compression or severe untreated sleep apnea)~* Decreased growth velocity (\< 1.5 cm/yr) over a period of 6 months or evidence of growth plate closure (proximal tibia, distal femur)~* Treated with growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic steroids in the previous 6 months or treatment greater than 6 months at any time~* Greater than 1 month treatment with oral corticosteroids (low-dose ongoing inhaled steroid for asthma, or intranasal steroids, are acceptable) in the previous 12 months~* Planned or expected to have limb-lengthening surgery during the study period. Subjects with previous limb- lengthening surgery may enroll if surgery occurred at least 18 months prior to the study and healing is complete without sequelae.~* Planned or expected bone-related surgery (ie. surgery involving disruption of bone cortex, excluding tooth extraction), during the study period. Subjects with previous bone-related surgery may enroll if surgery occurred at least 6 months prior to the study and healing is complete without sequelae.~* Had a fracture of the long bones or spine within 6 months prior to screening~* History of severe untreated sleep apnea~* New initiation of sleep apnea treatment (e.g. CPAP or sleep apnea-mitigating surgery) in the previous 2 months prior to screening~* History of hip surgery or hip dysplasia atypical for achondroplastic subjects~* History of clinically significant hip injury in the 30 days prior to screening~* History of slipped capital femoral epiphysis or avascular necrosis of the femoral head~* Abnormal findings on baseline clinical hip exam or imaging assessments that are determined to be clinically significant~* Concurrent disease or condition that would interfere with study participation or safety evaluations, for any reason~* Condition or circumstance that places the subject at high risk for poor treatment compliance or for not completing the study

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Active BMN 111 (Type: EXPERIMENTAL): Daily subcutaneous injection of 15 micrograms per kilogram BMN111
- Placebo (Type: PLACEBO_COMPARATOR): Daily subcutaneous injection of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).